Design Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial for its gene-targeted treatment DT-216P2 in healthy volunteers, with patient dosing for Friedreich Ataxia (FA) set to ...
Download BD+C's Annual Reports, including the 2025 and 2024 Healthcare Annual Reports and the 2024 and 2023 Multifamily Annual Reports. Building Design+Construction’s 2025 Healthcare Annual Report ...
To supplement amounts presented in our consolidated financial statements determined in accordance with accounting principles generally accepted in the U.S. ("GAAP"), the Company uses certain non-GAAP ...
To supplement amounts presented in our consolidated financial statements determined in accordance with accounting principles generally accepted in the U.S. ("GAAP"), the Company uses certain non-GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback